HIT Intelligence Briefing
Health In Tech · September 24, 2026
The employer health market is entering a period in which elevated cost growth is no longer best understood as a temporary post-pandemic correction. Utilization, prescription drug intensity, provider prices and high-severity claims are all compounding at an exponential rate. That combination is changing what employers need from brokers, TPAs, MGUs, carriers and stop-loss partners.
The national spending curve remains structurally steep. U.S. health spending rose 7.2% to $5.3 trillion in 2024. CMS now projects 7.3% growth in 2025 and 6.3% in 2026, with total spending reaching $9.0 trillion by 2034. Over 2025–2034, spending is projected to grow 5.4% annually, compared with 4.1% for GDP, lifting healthcare’s share of the economy from 18.0% to 20.6%.
Sources: CMS historical data · CMS 2025–2034 forecast
Employer cost pressure is intensifying even after plan changes. Large employers anticipate a median 9% trend for 2026 before plan-design action and 7.6% afterward; on a compounded basis, 2026 costs are expected to be 62% above 2017 levels. Mercer’s broader employer survey projects a 6.7% average increase after planned actions, the highest in 15 years, pushing average cost above $18,500 per employee. The estimates differ because the samples and measures differ, but both point in the same direction: benefit budgets are again outpacing general inflation.
Sources: Business Group on Health · Mercer
Pharmacy is becoming a core financing problem, not a benefit carve-out. Employers reported that pharmacy represented 24% of healthcare spending in 2024 and projected pharmacy trend of 11% in 2025 and 12% in 2026 before plan changes. CMS separately projects retail prescription drug spending grew 11.1% in 2025, driven in part by diabetes and obesity drug utilization.
Sources: Business Group on Health · CMS
Alternative funding is moving down-market. Sixty-seven percent of covered workers were in self-funded plans in 2025, while 37% of covered workers at firms with 10–199 employees were in level-funded arrangements. Among large employers’ self-funded enrollees, 75% were in plans with stop-loss protection. Department of Labor filings show the share of small self-insured plans reporting stop-loss increased from 23% in 2014 to nearly 59% in 2023, although Form 5500 data omit many small plans and understate some stop-loss use.
Sources: KFF · Department of Labor
Transparency is moving from disclosure toward usable infrastructure. New hospital price-transparency requirements have been enforceable since April 1, 2026, including median, 10th-percentile and 90th-percentile allowed amounts when negotiated charges are based on percentages or algorithms. A separate proposed Transparency in Coverage rule would restructure payer files around networks, utilization and change logs while reducing the reporting cadence from monthly to quarterly.
Sources: CMS hospital price transparency · CMS Transparency in Coverage proposal
AI adoption is outrunning governance maturity. State regulators report health insurers using AI across prior authorization, fraud detection, product pricing, plan design, risk adjustment and claims adjudication. The NAIC framework now emphasizes written governance, documentation, testing and third-party oversight; 12 states were piloting a regulatory evaluation tool as of March 2026.
Sources: NAIC
Affordability is becoming a workforce issue, not only a benefits issue. The average 2025 family premium reached $26,993, up 6% in one year, while wages rose 4% and inflation 2.7%. Workers contributed $6,850 on average toward family coverage. Organizations that rely primarily on higher deductibles or contributions risk improving the plan’s accounting position while worsening access, adherence and employee confidence.
Sources: KFF
Market Trends
Trend 1: Cost growth is broadening beyond unit-price inflation
The latest CMS forecast matters because it attributes near-term growth to continued use of services and goods, not merely higher prices. Private health insurance spending was projected to have grown 8.2% in 2025 after 8.8% in 2024. Hospital spending was projected to have grown 8.2% in 2025, following 8.9% in 2024, with utilization remaining above long-term averages. This is a more difficult cost environment than one driven by isolated contract renewals: unit-price negotiation alone cannot fully offset more encounters, more prescriptions and greater clinical intensity.
Sources: CMS
The historical comparison is equally important.
Average family premiums rose 26% from 2020 to 2025. That was roughly in line with cumulative wage growth of 28.6% and above cumulative inflation of 23.5%, but the one-year 2025 figures show premiums pulling ahead again. A return to routine cost shifting would meet a labor market in which affordability is already uneven: workers at firms with 10–199 employees contributed $8,889 on average toward family coverage, versus $6,227 at larger firms.
Sources: KFF
Executive Implication
Forecasting should separate three effects that are often blended into a single trend rate: unit cost, utilization frequency and claim severity. Employers and intermediaries should look for plan-modeling capabilities that can test each factor independently, compare multiple funding structures and show the employee-affordability effect before a design is selected.
Trend 2: Pharmacy economics are changing the shape of risk
GLP-1 coverage illustrates the tension between clinical value and budget timing. In 2025, 19% of firms with at least 200 workers, and 43% of firms with at least 5,000 workers covered GLP-1 drugs for weight loss in their largest plan. Among the largest employers offering coverage, 66% said the drugs had a significant effect on prescription spending. Meanwhile, 90% of employers covering GLP-1s for obesity required prior authorization, 54% required participation in weight-management programs and 48% imposed a BMI or comorbidity threshold beyond the FDA indication.
Sources: KFF · Business Group on Health
The conventional debate to cover or exclude, misses the operational problem. Near-term drug costs are observable; downstream medical offsets are slower, population-dependent and vulnerable to discontinuation. This makes static annual ROI claims less useful than cohort analysis that tracks persistence, clinical response, cardiometabolic risk and total cost over several years.
Specialty pharmacy raises a different transparency issue. The FTC found that, among the specialty generic drugs it examined for commercially insured members from 2020 through 2022, 63% were reimbursed by the three largest PBMs’ affiliated pharmacies at more than 100% above estimated acquisition cost, including 22% at markups above 1,000%. Across commercial and Medicare Part D claims, affiliated pharmacies generated more than $7.3 billion in dispensing revenue above estimated acquisition cost on the drugs studied over 2017–2022, and the PBMs generated an estimated $1.4 billion in spread-pricing income. These are findings from an interim staff study, not a complete accounting of every PBM contract, but they strengthen the case for contract-level audit rights.
Sources: FTC
Executive Implication
Pharmacy evaluation should extend beyond headline rebates. Plan sponsors should prioritize net-cost reporting at the drug and channel level, acquisition-cost benchmarks, specialty-pharmacy steering analysis, rebate and fee reconciliation, formulary-change controls and the ability to combine pharmacy and medical claims.
Trend 3: Cancer and advanced therapies are increasing claim volatility
Cancer remained the condition most frequently identified among employers’ top three cost drivers in 2025, cited by 88% of respondents in the Business Group on Health survey. Seventy-four percent reported already seeing an effect from higher cancer prevalence. At the same time, the FDA reported in January 2026 that its biologics center had approved close to 50 cell and gene therapies over the preceding decade, with continued product development expected.
Sources: Business Group on Health · FDA
For self-funded employers, the relevant risk is not only average trend. A small number of cases can materially change monthly cash flow, renewal pricing and specific stop-loss performance. For stop-loss carriers and MGUs, the problem is the interaction among rapidly changing treatment pathways, limited experience data and contract language governing eligibility, clinical trials, centers of excellence and high-cost drugs billed under either the medical or pharmacy benefit.
Executive Implication
Organizations should prioritize early identification of high-severity risk, but avoid treating prediction as certainty. The more durable capabilities are scenario ranges, clinical review, coordinated medical-pharmacy data, clear reimbursement rules and traceable decisions about lasers, exclusions, aggregating specific deductibles and renewal terms.
Trend 4: Self-funding is becoming more segmented
Self-funding is mature among large employers but is increasingly packaged for smaller groups through level-funded arrangements and stop-loss protection. KFF found that 67% of covered workers were self-funded in 2025, essentially unchanged from 66% a decade earlier, but the structure varies sharply by employer size: 80% at firms with 200 or more employees compared with 27% at firms with 10–199. Thirty-seven percent of covered workers at smaller firms were in level-funded plans.
Sources: KFF
The strategic change, therefore, is less “more self-funding everywhere” than wider segmentation of funding options. Smaller groups are gaining access to arrangements that combine fixed monthly payments with experience-sensitive economics. That increases the importance of explaining surplus provisions, terminal liability, run-out claims, renewal underwriting, disclosure requirements and the difference between plan assets and stop-loss coverage.
Executive Implication
Brokers and employers need side-by-side modeling of fully insured, level-funded and self-funded scenarios using consistent assumptions. Decision support should expose downside risk, cash-flow timing, contract terms and employee impact—not simply the most attractive first-year rate.
Trend 5: Provider consolidation limits what benefit design can accomplish
GAO’s 2025 review found that hospital-physician consolidation can increase prices and spending, including through migration of services to more expensive hospital-based settings, while the reviewed evidence generally found no quality improvement. Separately, private-plan spending on hospital services rose nearly 50% between 2012 and 2022.
Sources: GAO consolidation review · GAO price-transparency review
The labor outlook adds another layer. BLS projects healthcare and social assistance employment to grow 8.4% from 2024 to 2034 and add roughly two million jobs, while healthcare occupations are expected to generate about 1.9 million openings a year from growth and replacement needs. Labor supply will remain a material input to provider costs even if general inflation moderates.
Sources: BLS employment projections · BLS healthcare occupations
Executive Implication
Network strategy should move beyond discount percentages. Buyers increasingly need allowed-cost comparisons, site-of-care analysis, quality measures, referral-pattern visibility and member navigation that can redirect care without creating clinically inappropriate barriers.
Regulatory Watch
Transparency in Coverage and hospital price data
CMS began enforcing the 2026 hospital price-transparency changes on April 1. When a payer-specific negotiated charge is based on a percentage or algorithm, hospitals must now report the median, 10th-percentile and 90th-percentile allowed amounts and the number of allowed amounts used. CMS is also seeking comment, due August 31, 2026, on further standardization and comparability.
Sources: CMS
For health plans, a December 2025 proposed rule would eliminate clinically implausible provider-rate combinations, organize in-network files at the network level, add utilization and change-log files, aggregate out-of-network allowed amounts by market type and move file publication from monthly to quarterly. Because this remains proposed, organizations should not treat the design as final. Its direction is nevertheless clear: regulators want fewer unusable terabytes and more comparable pricing information.
Sources: CMS
Operational Response
Preserve data lineage now. Pricing analytics should retain the source file, effective date, network identity, billing-code normalization and methodology used for every comparison. Transparency without provenance will not withstand procurement, actuarial or fiduciary scrutiny.
No Surprises Act
In May 2026, the Departments finalized changes intended to improve federal independent dispute resolution by streamlining communication among payers, providers and certified IDR entities and clarifying timelines and processes. This does not remove the underlying operational burden; it increases the importance of accurate qualifying-payment-amount calculations, notice controls, dispute tracking and deadline management.
Sources: CMS
Operational Response
Plans and administrators should maintain a defensible claim-level audit trail from initial adjudication through open negotiation and IDR, including the data used to calculate the qualifying payment amount and the reason for any adjustment.
Mental health parity
The 2024 MHPAEA final rule remains under litigation. The Departments’ May 2025 policy states that they will not enforce provisions that are new relative to the 2013 rule for noncompliance occurring before a final litigation decision and for 18 months afterward. The underlying statute remains in effect, including the requirement to perform and document comparative analyses of nonquantitative treatment limitations.
Sources: Department of Labor 2025 report to Congress
Access remains the substantive issue. Only 70% of employers in KFF’s 2025 survey believed their largest plan provided timely access to mental health services, versus 92% for primary care and 89% for specialty care.
Sources: KFF
Operational Response
Do not interpret enforcement relief as permission to pause parity work. Plans should continue testing authorization rules, reimbursement, provider-network access, concurrent review and other NQTLs against analogous medical and surgical benefits.
Cybersecurity and health-data governance
HHS’s proposed HIPAA Security Rule update would require, among other measures, written asset inventories and network maps, multi-factor authentication, encryption, vulnerability scans at least every six months, annual penetration tests, network segmentation, annual compliance audits and more prescriptive business-associate verification. The rule is not final; the current Security Rule remains in effect.
Sources: HHS
Operational Response
Procurement should treat security evidence as an operating requirement, not a questionnaire. Organizations should prioritize data minimization, role-based access, documented recovery objectives, independent testing, subcontractor visibility and explicit allocation of breach-response responsibilities.
AI, Data and Technology
The market is moving from AI experimentation to accountable deployment. NAIC reports that health insurers already use AI in prior authorization, fraud detection, pricing, plan design, data processing, risk adjustment and claims adjudication. Its Model Bulletin makes a critical point: using AI does not change an insurer’s obligations under existing law. Governance, documentation, testing and third-party oversight travel with the decision.
Sources: NAIC issue brief · NAIC AI overview
Health-data standards are evolving in parallel. ONC’s HTI-1 rule established algorithm-transparency requirements for predictive tools embedded in certified health IT and made USCDI Version 3 the certification baseline as of January 1, 2026. The rule is aimed at clinical technology, but it signals a broader buyer expectation: decision-makers increasingly want to know what data a model uses, where it was validated, how performance is monitored and whether results vary across populations.
Sources: ONC
The central limitation is not a lack of algorithms. It is fragmented, delayed and inconsistently coded data. A model trained on incomplete eligibility files, stale provider information or separated medical and pharmacy feeds can produce a precise-looking answer that is operationally wrong.
Capabilities to prioritize over the next two to five years
- A governed inventory of models, rules and human decision points.
- Versioned inputs, outputs and configuration changes.
- Explainability appropriate to the decision’s financial and clinical consequence.
- Bias and performance testing across relevant populations.
- Human review and an appeal path for consequential decisions.
- Third-party model documentation and contractual audit rights.
- Interoperable medical, pharmacy, eligibility and provider data.
- Security controls designed for the full data supply chain.
AI should be evaluated by the quality and defensibility of the decision process it supports, not by the presence of a conversational interface.
By the Numbers
- U.S. health spending rose 7.2% to $5.3 trillion in 2024
- The average 2025 family premium reached $26,993, up 6% in one year
- 67% of covered workers were in self-funded plans in 2025
- Pharmacy represented 24% of healthcare spending in 2024
- Cancer remained the condition most frequently identified among employers’ top three cost drivers in 2025, cited by 88% of respondents
- 63% of specialty generic drugs studied were reimbursed by the three largest PBMs’ affiliated pharmacies at more than 100% above estimated acquisition cost
Key Takeaway
As healthcare costs rise, funding models diversify, and regulatory and technology expectations become more demanding, the organizations best positioned for what comes next will be those that plan before renewal pressure forces a decision. That means connecting plan design, funding, underwriting, pharmacy, data, and member affordability within one forward-looking strategy instead of evaluating each in isolation.
Take the Next Step
Schedule a strategic planning session with our team to pressure-test your current approach, identify emerging risks and opportunities, and build a more adaptable plan for the next plan year and beyond.
